Bli medlem
Bli medlem

Du är här

2016-04-01

Biotec Pharmacon ASA: ArcticZymes awarded funding from the Horizon2020 programme

(Tromsø 01. April 2016) Biotec Pharmacon ASA ("Biotec",OSE: BIOTEC) is
pleased to announce that ArcticZymes, a subsidiary of Biotec
Pharmacon has received EUR 460.000 over the next four years in a
project funded by the European Framework Programme for Research and
Innovation, Horizon 2020.

"We are excited to participate in the new granted "Virus-X" EU
Consortium. It will allow ArcticZymes to expand its access to novel
molecular enzymes via the bioprospecting of a wide diversity of viral
genomes.", says Jethro Holter, Managing Director, ArcticZymes AS.

The project "Viral Metagenomics for Innovation Value" (Virus-X), is a
large collaboration project between a total of 15 partners from
European research institutes, universities and industry with a total
budget of nearly 8 M€, funded under Horizon2020 - Research and
Innovation Action (RIA). Viruses represent the largest reservoir of
unknown genetic diversity on earth and the project aim to advance the
understanding of viral ecosystems, diversity and virus-host interplay
by DNA sequencing environmental libraries (metagenomes) from a number
of different biotopes. The project is driven by the expected large
innovation value and unique properties of viral gene products.
Through an analysis and discovery pipeline, new enzymes for molecular
biotechnology will be developed, and ArcticZymes is one of the
industrial partners that will participate developing and bringing new
viral enzymes to the market.

"This is a milestone and great achievement of ArcticZymes. This
acknowledges ArcticZymes experience and knowledge as a leading enzyme
company within in the EU system", say Svein Lien, CEO, Biotec
Pharmacon ASA.

For additional information:

Børge Sørvoll, CFO
+47 952 90187
borge.sorvoll@biotec.no (jh@arcticzymes.com)

Jetro Holter, MD ArcticZymes
+47 468 59146
jh@arcticzymes.com

About Biotec Pharmacon:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS
and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and
markets novel immunomodulating products, including Woulgan®, a
premium priced product in the advanced wound care market. ArcticZymes
develops, produces and markets enzymes of marine origin used in
molecular DNA technologies and diagnostics.

-----------------------------------------------------------
http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=346529...
http://mb.cision.com/Main/1090/9946870/495264.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.